NSABP Members' Area
  Password Protected - Access
  Limited to NSABP Participating
  Institutions Only


NSABP Foundation, Inc.



General NSABP Information
  Contact the NSABP
  Pathology Section
  Future Meetings
  NSABP Newsletters
  Media Info on cMYC Study
  Media Info on STAR
  Employment

Clinical Trials Information
  Clinical Trials Overview
  Protocol Chart
  Never Say Lost

Treatment Trials Information
  Protocol B-37
  Protocol B-39
  Protocol B-40
  Protocol B-41
  Protocol B-42
  Protocol B-43
  Protocol BP-59
  Protocol R-04

Prevention Trials Information
  Protocol P-1 - BCPT
  Protocol P-2 - STAR
  BreastCancerPrevention.com

Bibliography of Publications

Related Web Sites

About the NSABP Web Site



Medical Search Engines



To report problems, ask
questions or make comments,
please send e-mail to:
Webmaster@nsabp.pitt.edu

Annotated Bibliography of NSABP Publications


International Expert Panel on the Use of Primary (Preoperative) Systemic Treatment of Operable Breast Cancer: Review and Recommendations
Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, Howell A, Costa SD, Beuzeboc P, Untch M, Blohmer JU, Sinn HP, Sittek R, Souchon R, Tulusan AH, Volm T, Senn HJ
Journal of Clinical Oncology 2003 July 1;21(13):2600-2608

Abstract
Primary systemic therapy (PST) represents the standard of care in patients with locally advanced breast cancer. In addition, there is increasing information on PST in operable breast disease that supports the use of PST in routine practice. However, current regimens and techniques vary. To address this concern, a group of representatives from breast cancer clinical research groups in France, Germany, Italy, the United Kingdom, and the United States reviewed all available data on prospective randomized trials in this setting. Recommendations are made regarding terminology, indications, regimen, diagnosis before treatment, monitoring of efficacy, tumor localization, surgery, pathologic evaluation, and postoperative treatment.

Erratum in: Journal of Clinical Oncology 2003 Dec 1;21(23):4469